Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TIL
TIL logo

TIL Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Instil Bio Inc (TIL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
7.500
1 Day change
-0.79%
52 Week Range
42.790
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Instil Bio Inc (TIL) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. The technical indicators show a bearish trend, and there are no positive catalysts, news, or trading signals to support a strong entry point. Additionally, the stock is oversold, and the short-term price trend suggests further downside potential in the coming days and weeks.

Technical Analysis

The MACD histogram is negative and expanding downward, indicating bearish momentum. The RSI is at 7.354, signaling the stock is oversold. Moving averages are bearish, with SMA_200 > SMA_20 > SMA_5. Key support is at 7.585, with resistance at 8.135. The stock has a 70% chance of declining further in the next week.

Positive Catalysts

  • NULL identified. No recent news or trading signals to indicate a positive catalyst.

Neutral/Negative Catalysts

  • Bearish technical indicators, oversold RSI, and a high probability of further short-term price decline (-8.09% in the next week). Lack of positive news or trading activity.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target updates available.

Wall Street analysts forecast TIL stock price to rise
Analyst Rating
0
Wall Street analysts forecast TIL stock price to rise
Buy
Hold
Sell
0
Current: 7.560
sliders
Low
0
Averages
0
High
0
0
Current: 7.560
sliders
Low
0
Averages
0
High
0
Baird
Outperform -> Neutral
downgrade
$180 -> $7
AI Analysis
2026-01-06
Reason
Baird
Price Target
$180 -> $7
AI Analysis
2026-01-06
downgrade
Outperform -> Neutral
Reason
Baird downgraded Instil Bio to Neutral from Outperform with a price target of $7, down from $180, after the company discontinued clinical development of AXN-2510.
Baird
Jack Allen
Outperform -> Neutral
downgrade
$180 -> $7
2026-01-06
Reason
Baird
Jack Allen
Price Target
$180 -> $7
2026-01-06
downgrade
Outperform -> Neutral
Reason
Baird analyst Jack Allen downgraded Instil Bio to Neutral from Outperform with a price target of $7, down from $180. The stock in midday trading is down 47%, or $5.79, to $6.50. Baird cites the discontinuation of AXN-2510 for the downgrade. Instil terminated its licenses with ImmuneOnco surrounding AXN-2510 and AXN-27M. The analyst is "disappointed" by the news, saying the early data for AXN-2510 was "encouraging." Further details surrounding the decision to discontinue to AXN-2510 are not being disclosed, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TIL
Unlock Now

People Also Watch